Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096680 | 0.90 | NR1H4 (0.45) | NR1H4GABRB3GABRA2GABRB2CCNK | |
| SCHEMBL12188553 | 0.88 | NR1H4 (0.45) | NR1H4GABRB3GABRA2GABRB2CCNK | |
| SCHEMBL27896017 | 0.87 | NR1H4 (0.43) | NR1H4GABRB3GABRA2GABRB2CCNK | |
| SCHEMBL498227 | 0.87 | NR1H4 (0.47) | NR1H4GABRB3GABRA2GABRB2CCNK | |
| SCHEMBL12878994 | 0.80 | NR1H4 (0.39) | NR1H4GABRB3GABRA2GABRB2CCNK | |
| SCHEMBL498141 | 0.79 | NR1H4 (0.49) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL498805 | 0.77 | NR1H4 (0.56) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL27896015 | 0.76 | NR1H4 (0.39) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL12168764 | 0.76 | NR1H4 (0.37) | NR1H4CCNKCCND3GSK3BCDK7 | |
| SCHEMBL2130842 | 0.75 | NR1H4 (0.46) | NR1H4GABRB3CCNKCCND3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| CN-105884758-B | Tricyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-01 | — | — | US | disclosed |
| CN-105884758-A | Tricyclic compound and application thereof to drugs | 广东东阳光药业有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885GABRB3 423/4885GABRA2 637/4885 |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | NR1H4 1/4885GABRB3 1208/4885GABRA2 1685/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | NR1H4 1/4885GABRB3 448/4885GABRA2 1161/4885 |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | NR1H4 1/4885GABRB3 1208/4885GABRA2 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.